Chemoprevention of N-Methyl-N-Nitrosourea Induced Mammary Carcinogenesis with Raloxifene and Melatonin: Metabolic Changes in Female Rats

Acta Veterinaria Brno

Volumn 71, Issue 2, 2002, Pages 235-242

  Chamilova M ^a   Kubatka, P ^a   Kalicka K ^a   Adamekova E ^a   Bojkova B ^a   Ahlers, I ^a   Ahlersova E ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Breast cancer; Chemoprevention; Female rats; Melatonin; Raloxifene

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOHYDRATE; CHOLESTEROL; GLUCOSE; GLYCOGEN; LIPID; MALONALDEHYDE; MELATONIN; METHYLNITROSOUREA; PHOSPHOLIPID; RALOXIFENE; TRIACYLGLYCEROL; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BREAST CARCINOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CARBOHYDRATE METABOLISM; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FREQUENCY ANALYSIS; GLUCOSE BLOOD LEVEL; LATENT PERIOD; LIPID METABOLISM; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; THYMUS; TISSUE LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR VOLUME;

ANIMALIA;

EID: 0344628523     PISSN: 00017213     EISSN: None     Source Type: Journal    
DOI: 10.2754/avb200271020235     Document Type: Article

References (28)

1. ABOAGYE, EO, BHUJWALLA, ZM 1999: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59: 80-84
2. ANDERSON, PW, COX, DA, SASHEGYI, A, PAUL, S, SILFEN, SL, WALSH, BW 2001: Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 39: 71-77
3. BAILEY, CJ, ATKINS, TW, MATTY, AJ 1974: Melatonin inhibition of insulin secretion in the rat and mouse. Hormone Res 5: 21-28
4. BARTLETT, GR 1959: Phosphorus assay in column chromatography. J Biol Chem 234: 466-468
5. BLASK, DE 1993: Melatonin in oncology. In: Yu, HS, Reiter, RJ: Melatonin: Biosynthesis, Physiological Effects and Clinical Applications. CRC Press, Boca Raton, pp. 447-475
6. rd 1998: Effects of oestrogens and selective oestrogen 63receptor modulators on serum lipoproteins and vascular function. Curr Opin Lipidol 9: 575-586
7. COL, NF, ECKMAN, MH, KARSS, RH et al. 1997: Patient-specific decision about hormone replacement therapy in postmenopausal women. JAMA 277: 1140-1147
8. COS, S, FERNÁNDEZ, F, SÁNCHEZ-BARCELÓ, EJ 1996: Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci 58: 2447-2453
9. COS, S, SÁNCHEZ-BARCELÓ, EJ 2000: Melatonin and mammary pathological growth. Front Neuroendocrinol 21: 133-170
10. DELMAS, PD, BJARNASON, NH, MITLAK, BH, RAVOUX, AC, SHAH, AS, HUNSTER, WJ et al. 1997: Effect of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl J Med 337: 1641-1647
11. DESSI, S, BATETTA, B, PULISCI, D, SPANO, O, CHERCHI, R, LANFRANCO, G, TESSITORE, L, COSTELLI, P, BACCINO, FM, PANI, P 1992: Altered pattern of lipid metabolism in patients with lung cancer. Oncology 49: 436-441
12. EL-BAYOUMY, K 1994: Evaluation of chemopreventive agents againts breast cancer and proposed strategies for future clinical intervention trials. Carcinogenesis 15: 2395-2420
13. GUERRERO, JM, REITER, RJ 1992: A brief survey of pineal gland-immune system interrelationships. Endocr Res 18: 91-113
14. HOZUMI, Y, KAWANO, M, JORDAN, VC 2000: In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen. Eur J Endocrin 143: 427-430
15. CHAMILOVÁ, M, BOJKOVÁ, B, KUBATKA, P, KALICKÁ, K, ADÁMEKOVÁ, E, AHLERS, I, AHLERSOVÁ, E 2001: Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats by tamoxifen and melatonin: metabolic alterations. Biologia (Bratislava) 56: 565-571
16. KANEL, KT, WOLMARK, N, THOMPSON, PD 1997: Delayed severe hypertriglyceridemia from tamoxifen. New England J Med 337: 281
17. LISSONI, P, BARNI, S, CRISPINO, S, TANCINI, G, FRASCHINI, F 1989: Endocrine and immune effect of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol 25: 789-795
18. OLEKSIK, AM, DUONG, T, PLIESTER, N, ASMA, G, POPP-SNIJDERS, C, LIPS, P 2001: Effect of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab 86: 2763-2768
19. QUAY, WB, GORRAY, KC 1980: Pineal effect on metabolism and glucose homeostasis: evidence for lines of humoral mediation of pineal influences on tumour growth. J Neural Transm 47: 107-120
20. ROE, JH, DAILEY, R 1966: The determination of glycogen with anthrone reagent. Analyt Biochem 15: 245-250
21. ROSE, G, BLACKBURN, H, KEYS, A, TAYLOR, HL, KANNEL, WB, PAUL, O, REID, DD, STAMLER, J 1974: Colon cancer and blood cholesterol. Lancet 1: 181-183
22. SATCH, K 1978: Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 90: 37-43
23. SCOTT, JA, CAMARA, CC, EARLY, JE 1999: Raloxifene: A selective estrogen receptor modulator. Am Fam Physician 60: 1131-1139
24. SHIMA, T, CHUN, S-J, NIIJIMA, A, BIZOT-ESPIARD, J-G, GUARDIOLA-LEMAITRE, B, HOSOKAWA, M, NAGAI, K 1997: Melatonin suppresses hyperglycemia caused by intracerebroventricular injection of 2-deoxy-D-glucose in rats. Neurose Lett 226: 119-122
25. SPIEGEL, RJ, SCHAEFER, EJ, MCGRATH, LT, EDWARDS, BK 1982: Plasma lipid alterations in leukemia and lymphoma. Am J Med 72: 775-782
26. VAUGHAN, MK, VAUGHAN, GM 1993: Metabolic and thyroidal consequences of melatonin administration in mammals: In: Yu, HS, Reiter, RJ, Eds.: Melatonin - Biosynthesis, Physiological Effects, and Clinical Implications. CRC, Boca Raton, pp. 311-347
27. WELSCH, CW 1985: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res 45: 3415-3443
28. ZLATKIS, A, ZAK, B, BOYLE, AJ 1953: A new method for the direct determination of cholesterol. J Lab Clin Med 41: 486-490